Home/Pipeline/VTAMA (tapinarof)

VTAMA (tapinarof)

Plaque Psoriasis

CommercialLaunched

Key Facts

Indication

Plaque Psoriasis

Phase

Commercial

Status

Launched

Company

Roivant Sciences

About Roivant Sciences

Founded in 2014, Roivant Sciences operates through a unique 'Vant' model, creating nimble subsidiary companies focused on specific therapeutic areas including Immunovant (autoimmune diseases), Priovant (severe autoimmune conditions), and Pulmovant (pulmonary diseases). The company has demonstrated strong execution with multiple successful Phase 3 trials and commercial launches, including VTAMA for plaque psoriasis. Roivant trades on NASDAQ under ticker ROIV and maintains a broad pipeline of investigational drugs across various therapeutic areas and development phases.

View full company profile

Therapeutic Areas

Autoimmune Diseases Rare Diseases Pulmonary Diseases Dermatology Ophthalmology

Other Plaque Psoriasis Drugs

Drug	Company	Phase	Status
Sorilux (calcipotriene) Foam	Mayne Pharma Group	Approved	Commercial
Psoriasis Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting